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Tumor-assoated markers defined by monoclonal antibodies have proven useful to phenotype
bladder tumours. In order to evaluate the prostc value of such markers, we performed an immunohisto-
chical stucdy on 57 transitional cell carno (23 imfiltratie and 34 suefiial tumours) and ten healthy
bladders usin monocknal antibodies ainst the extenal domam of the epidenal growth factor receptor
(EGFR) and against the tumour-associated antigens T43, 19A211 and T138. Immunohistochemistry was
performed on frozen sections usin a two-step alalin phosphatase method. The staining pattern obtained
with each antibody was analysed o to the TNM cassif_aion, and results were analysed rding to
the sub t cinical course. 19A211 pferenftially sained uperficial tumours, and T43, T138 and EGFR
preferentially stained invasive tumours- Three monoclmal antibodies a re to have prognostic vahle, since
progression rate survivl was significantly (log-rank test) assocated with their expon of EGFR
(P=0.017), T138 (P=0.0009) and T43 (P=0.031). T138 expression was found to have an independent
significant prognostic value usin a stepwise logistic regression. T138 antibody may add significant information
to clssicl patholoical parmeters.
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Human bladder tumours have heterogeneous biological
behaviour. Epidemiological studies and present knowledge of
the natural history of bladdr cancers suggest that they have
different growth potentials. At initial presentaton, some grow
superficially (Ta-TI tumours), while others are muscle infil-
trative (>T1 tumours). Infiltration does not usually follow
superficial growth. Despite the emergence of new tumoral
outcome indicators, e.g. cell DNA content (Thbukait et al.,
1982; Dolbeare et al., 1983) it is difficult to predict tumour
progression precisely: classical clnicopathological prognostic
factors are not able to predict which superficial tumours will
lead to infiltration and which infiltrating tumours will
generate distant metastases. The ability to identify high-risk
patients would enable us to choose between conservative and
radical treatment at an early stage and to better nvestigate
multimodal therapy in advanced diseas. The need for new,
independent prognostic markers has led to studies of anti-
bodies for determining bladder tumour immunophenotype.
Using hybridoma technology, several monoclonal anti-
bodies against tumour-associated antgens have been devel-
oped (Young et al., 1985). Experimental data suggest that
malignant transformation can be accompanied by
modifications of the cell phenotype, e.g. the loss of antgens
usually present at the cell surface or the appearance of new
antigens. Potential markers inchlde T43 and T138 antigens,
which are glycoproteins of respectively M, 85 000 and Mr
25 000, defined by monoclonal antibodies produced with the
hybridoma method (Fradet et al., 1990). T43 and T138
antigens show sgnifintly increased expression in infiltrative
tumours and have potential prognostic value: it has been
suggsted that T43- and T138-positive bladder tumours have
a poorer prognosis and that the expression ofT138 antigen is
a better single indicator than ploidy (determined by flow
cytometry). In low-grade superficial tumours (Fradet et al.,
1987), it has been reported that antibody 19A211, which
identifies a sialylated epitope on a cytoplasmic protein com-
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plex of 100000-200000 M, is significantly more strongly
expressed in this group and that down-regulation of this
antigen may be associated with inreased recurrence nsk.
Recently, attention has been drawn to growth factors,
since an autocrine loop may be involved in the transforma-
tion or progression of human cancer. Epidermal growth fac-
tor (EGF) is a 53 amino acid peptide originally isolated
(Cohen, 1962) from the submaxillary gland of the male
mouse. It is a potent stimulator of growth and division in
cells of many different types. It is now clear that EGF
belongs to a family of related peptides which are assocated
with the malignant phenotype, such as transforming growth
factor alpha (TGF-a). The actions of EGF and TGF-a are
mediated by binding to a specific membrane receptor which
has a close strncturl relationship with the oncogene product
of erb-B (Gulfick, 1990). The intracellular portion of EGFR
has an assocated tyrosine kinas domain and three tyrosine
residues which are autophosphorylated after binding of EGF
and induce signal transmion to the nucleus (King, 1985).
Inceased levels of this receptor have been found in several
cancers, including bladder cancer. Previous studies (Neal et
al., 1985; Messing et al., 1987) have shown that EGFR is
more strongly expressed in high-grade and deep tumours and
that it could have predictive value for progression. It has also
been suggted that when EGFR is expressed on superficial
tumours or normal bladders there is inreased expresson in
the deep layer cells of the urothelium.
In this study we evaluated the prognostic value of expres-
sion of the aforementioned monoclonal antibodies by means
of immunohistochemistry.
Materiab and shos
Samples were obtained at surgery from patients (TCC) and
from cadaveric donors (normal urothelium), embedded in
OCT, frozen immediately in isopentane cooled in liquid
nitrogen and stored at -W80C until use. Ten normal uro-
theium samples and 57 TCCs (34 superficial and 23 muscle-
invasive tumours: 18 grade 1, 18 grade 2, and 21 grade 3 or
14 Ta, 20 T1, 14 T2, eight T3, and one T4) were used.Immunohistochemical procedures
Cryostat sections were air dried. Slides were immersed in
cold acetone for 15 mmn and then rehydrated. Slides were
then preincubated for 30 min with phosphate-buffered saline
(PBS) + 10% normal rabbit serum (NRS) + 1% bovine
serum albumin (BSA) and incubated for 45 min with the
primary antibody, a monoclonal antibody against the exter-
nal domain of EGFR (EGFr-Abl, Oncogene Science) at 1:50
dilution; mouse monoclonal antibodies (MAb) 19A211, T43
(IgGl antibodies) and T138 (IgM antibody) from Y. Fradet
were used as undiluted tissue culture supernatants. As a
negative control we used isotyped irrelevant IgM and IgG in
PBS (0.15 M sodium chloride + 10% NRS + 1% BSA). Slides
were washed in PBS and then incubated for 45 min with the
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second antibody at 1:50 dilution (D314, alkaline phos-
phatase-conjugated rabbit antimouse immunoglobulins from
Dako). Slides were washed again in PBS. Finally, alkaline
phosphatase was revealed with 10 ml of substrate [2 mg of
naphthol AS-MX phosphate (Sigma) + 0.2 ml of N-N-
dimethylformamide, (Merck) + 9.8 ml of Tris buffer 0.1 M
pH 8.2 + 10 i1 of levamisole 1 M (Sigma) to inhibit
endogenous alkaline phosphatase] and 10 mg of fast red salt
(Sigma) for 30 min in the dark. Samples were then washed in
double-distilled water (DDW), counterstained and mounted
in Immumount (Shandon) under coverslips. A sample was
considered negative when immunostaining was the same as a
negative control. Positive samples were assessed for staining
intensity by two examiners. In case of disagreement, a third
examination was decisive.
immunophenotyping of normal and tumoral
samples
19A211
70.6
(24 34)
47.8
(11 23)
77.7
(14 18)
55.5
(10 18)
52.4
(11 21)
40
(4 10)
T138
26.5
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60.9
(14 23)
27.8
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38.9
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52.4
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20
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T43
29.4
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52,2
(12 23)
38.9
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27.8
(5 18)
47.6
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0
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EGF-R
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69.6
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Fue 3 T43 staining in a superficial TCC (x 240). Arrow
shows cluster of positive cells.
Fige I 19A211 staining in a superficial TCC (x 240). Arrow
shows positive staimnng.
Figwe 2 19A211 staining in an invasive and high-grade TCC
(x 60).
Figwe 4 T43 staining in an invasive TCC (x 60). Arrow shows
positive staining.
Figwe 5 T138 staining in a superficial TCC (x 60). * shows
positive stromal cells.
Table I Results of
Superficial tumours
Infiltrating tumours
GI
G2
G3
Healthy tissuesEGR T13 and T43 expression in bldder canw
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Clinical data and statistical analysis
We defined superficial TCC progression as the occurrence of
muscle infiltration and infiltrative TCC progression as the
occurrence of patent metastases or death from disease pro-
gression. Clinical data were managed on the Medlog Soft-
ware program. Survival probability was estimated by the
Kaplan-Meier method and results for the different groups
were compared by the log-rank test. Statistical analysis for
staining pattern was performed using the Statview program.
The statistical significance of differences between groups was
determined by using Student's t-test and the chi-square test.
A stepwise logistic regression (BHDP Software) was used to
compare the independence of each prognostic factor.
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Figwe 6 T138 staining in an invasive TCC (x 24).
Results
Immunohistochemistrv
Immunostaining patterns are reported in Table I. 19A211
antigen was more strongly expressed in superficial tumours
(P = 0.05) (Figures 1 and 2) and there was no good correla-
tion with tumour grade. T43 (Figures 3 and 4) and T138
(Figures 5 and 6) antigens were more strongly expressed in
deep tumours (P<0.05). Expression of the last two antigens
correlated with high-grade tumours (P = 0.05). T138 expres-
sion in normal bladders and in unstained tumour samples
was restricted to stroma endothelial cells. Finally, EGFR
expression was stronger in deep tumours (Figure 7), with no
difference according to grade. When it was expressed in
normal bladders or superficial tumours, expression was
strongest in the basal layer cells (Figure 8).
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Fugwe 7 Strong EGFR staining in an invasive TCC (x 60).
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Figwe 8 Increased EGFR expression in the deep layer of a
superficial TCC (x 240).
P= 0.0009
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Fugwe 9 Progression-free survival probabilities according to (a)
EGFR, (b) T138 and (c) T43 immunostaining. El, positive, *,
negative.
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Survivalprobability
Surface antigen phenotypes correlated with the clinical find-
ings at the time of sampling and with outcome. As expected,
a low incidence ofprogression (14.7%, 5/34) was observed in
patients with superficial (Ta-TI) tumours, contrasting with a
progression rate of 82.6% (19/23) in patients with deeply
infiltrating tumours. Tumour stage (P<0.001) and his-
tological grade (0.001 <P<0.01) were significant predictors
of outcome for the entire group. Antigen phenotype cor-
related with clinical progression. Only three markers had
significant predictive value for the progression rate using the
log-rank test (Figure 9): EGFR (P = 0.017), T138
(P = 0.0009) and T43 (P = 0.031). The cancer progressed
only in 6/25 (24%) patients with EGFR-negative samples,
6/34 (17.6%) with T138-negative samples and 11/35 (31.4%)
with T43-negative samples. In contrast, the cancer progressed
in 18/32 (56.3%) patients with EGFR-positive samples, 18/23
(78.3%) with T138-positive samples and 13/22 (59.1%) with
T43-positive samples. Using the stepwise logistic regression,
two factors appear to have a significant and independent
prognostic value: stage (P = 0.0001) and T138 expression
(P= 0.006).
Discussion
The pattern of 19A21 1, T43 and T138 monoclonal antibodies
staining in our tumour panel is in accordance with previous
descriptions (Fradet, 1987). 19A211 was detected in approx-
imately 60% of papillary superficial tumours (Ta/Tl) and in
situ carcinomas; in deeply infiltrating cancers (T2/T3) antigen
expression was only 35% of the tumours. In our study these
values were significantly different (respectively 70.6% and
47.8%). Antigens T43 and T138 have been described as
cancer progression antigens (Fradet et al., 1990): T43 expres-
sion is limited to metabolically active cells of the proximal
kidney tubule and the basal cell layer of pluristratified
squamous epithelia. T43 was expressed in 15-20% of
superficial bladder tumours and 60% of invasive bladder
cancers in a previous study (Fradet et al., 1987); in ours,
these percentages were respectively 29.4% and 52.2%. T138
has been reported to be expressed in similar proportions on
bladder tumours, and our results confirm that it is expressed
in 26.5% of superficial and 60.9% of invasive tumours. It is
now known that the 25 kDa surface glycoprotein detected by
antibody T138 is restricted in normal tissues to endothelial
cells of blood and lymph vessels, as confirmed in this study.
As a result, it has been speculated that T138 could be
involved in the metastatic process.
Independent studies (Berger et al., 1987; Messing, 1990;
Neal et al., 1990) have shown that muscle-invasive tumours
are more likely than superficial tumours to be EGFR positive
when stained immunohistochemically. Our data are in agree-
ment with a statistical significant difference (69.6% vs 47%).
The greater expression of EGFR in invasive tumours of the
bladder could imply a role for this receptor in bladder
tumour invasiveness. The reason for the heterogeneity of
receptor distribution and particularly the increased expres-
sion from superficial to deep layer urothelial cells in healthy
bladders and in superficial tumours is not clear. It could be
partly because of the more active division of basal cells in
well-differentiated tumours, this difference being suppressed
in undifferentiated tumours in which cell-cell cohesions and
interactions are looser. Samples which express EGFR are not
necessarily dependent on EGF for growth: they may be
abnormal and be active whether or not EGF is bound to the
receptor.
The prognostic value ofDNA analysis ofbladder tumours,
in addition to clinicopathological parameter, remains con-
troversial. It has been shown (Fradet, 1990) that ploidy alone
is not an entirely reliable prognostic indicator because a
significant proportion of non-progressing tumours were
aneuploid, while a few samples from patients with cancer
progression were diploid (20%). We found an interesting and
significant predictive progression value for T43, T138 and
EGFR expression. In agreement with a prognosis study using
flow cytometry (Fradet et al., 1990), we found that T138 was
a better prognostic tool than T43. T138 is expressed on
epithelial tumoral cells and endothelial cells in stromal tissue.
In this evaluation, we considered a tumour to be positive
only if the epithelial cells were positive. Expression of T138
on endothelial cells was not taken into account in this
analysis. If confirmed, it would suggest that these two
tumour-associated antigens may be early indicators of
aggressiveness. EGFR is also a preferential tool to predict
progression, as shown previously (Neal et al., 1990). In
future, these biological markers should be evaluated for the
prediction of other clinical features, such as the recurrence
rate of superficial tumours and the response to systemic
treatment. Finally, given their prognostic value, these
markers could be useful for screening tumours at an early
stage when radical treatment is still a valid option. Combined
flow cytometry (FCM) analysis of DNA and antigen pheno-
typing with monoclonal antibodies has shown that expression
or non-expression of T43 and T138 increases the prognostic
value of progression of ploidy. In our study, the progression
rate was profoundly influenced by T138, T43 and EGFR
expression using the univariate analysis, but only T138 ex-
pression has an independent prognostic value, and this is a
new finding. These molecules, and especially T138, appear to
be useful markers of tumour aggressiveness, which may
influence therapeutic decisions. They should now be studied
on a larger panel of tumours and compared with ploidy
states. Simple and reproducible tests on a minimal amount of
tumour material and, possibly quantitative assay by enzyme-
linked immunosorbent assay or image analysis would give
these markers wide clinical usefulness in the management of
bladder cancer.
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